A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.

British Journal of Cancer
Chris ParkerD Dearnaley

Abstract

The lead time and over-detection associated with prostate-specific antigen (PSA) screening, and generational improvements in all-cause mortality, make prostate cancer outcome studies from the pre-PSA era difficult to interpret in a contemporary setting. We developed a competing-risks hazard model to estimate the natural history of screen-detected prostate cancer, and the impact of radical treatment on overall survival. The model of hazard of mortality was fitted to clinical outcome data from the pre-PSA era, and the effects of screening, generational mortality improvements and radical treatment were incorporated. Sensitivities to the choice of baseline data and values of key parameters were assessed. Lead-time estimates in men diagnosed aged 55-59 years were 14.1, 9.3 and 5.0 years for men with Gleason scores <7, 7 and >7, respectively, assuming biennial screening with 100% attendance. Central estimates of 15-year prostate cancer mortality for conservative management of screen-detected prostate cancer ranged from 0 to 2% for Gleason scores <7, 9 to 31% for Gleason score 7 and 28-72% for Gleason scores >7. For men aged 55-59 years at diagnosis, the predicted absolute 15-year survival benefit from curative treatment was 0, 12 and...Continue Reading

References

Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A SingerR Weichselbaum
Sep 28, 1998·JAMA : the Journal of the American Medical Association·P C AlbertsenM J Barry
Jun 24, 2000·Nature·S TuljapurkarC Boe
Aug 2, 2001·Journal of the National Cancer Institute·R F HoedemaekerF H Schröder
Jun 4, 2002·Statistical Methods in Medical Research·Per Kragh AndersenSusanne Rosthøj
Nov 2, 2002·BJU International·P W Nicholson, S J Harland
Apr 24, 2003·Health Technology Assessment : HTA·J DonovanUNKNOWN ProtecT Study Group
Jul 3, 2003·Journal of the National Cancer Institute·Matthew R CooperbergPeter R Carroll
Sep 23, 2003·The Journal of Urology·Filippos I KondylisPaul F Schellhammer
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tuukka MäkinenAnssi Auvinen
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
May 5, 2005·JAMA : the Journal of the American Medical Association·Peter C AlbertsenJudith Fine
May 13, 2005·The New England Journal of Medicine·Anna Bill-AxelsonUNKNOWN Scandinavian Prostate Cancer Group Study No. 4

❮ Previous
Next ❯

Citations

Jun 15, 2007·International Journal of Epidemiology·Richard M Martin
Aug 12, 2009·PharmacoEconomics·Natasha K StoutG Scott Gazelle
Aug 17, 2010·Clinical Interventions in Aging·Jaspreet SinghLeonard G Gomella
Dec 7, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Ravinder MohanPaul Schellhammer
May 7, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Roman GulatiRuth Etzioni
Sep 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing XiaRuth Etzioni
Oct 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H Ballentine CarterJonathan I Epstein
Aug 25, 2011·Biomarkers in Medicine·Mark R Haythorn, Richard J Ablin
Jan 10, 2009·Nature Clinical Practice. Urology·Caroline M MooreMark Emberton
Feb 12, 2010·Future Oncology·Hashim U Ahmed, Mark Emberton
Jun 15, 2007·The New England Journal of Medicine·Donald S KaufmanRobert H Young
Sep 21, 2007·Histopathology·D M BerneyUNKNOWN Trans-Atlantic prostate group
Apr 4, 2008·BJU International·Jochen WalzPierre I Karakiewicz
Dec 13, 2007·Journal of the National Cancer Institute·Rune KvåleFreddie Bray
Dec 29, 2012·Journal of the National Cancer Institute. Monographs·H Ballentine Carter
May 1, 2015·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Leonardo de Oliveira Reis, H Ballentine Carter
Oct 26, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Suzanne K StegingaDavid Nicol
Sep 28, 2006·British Journal of Cancer·C MetcalfeJ L Donovan
Dec 23, 2008·Molecular Nutrition & Food Research·Peter D BaadeLauren J Krnjacki
Mar 30, 2018·Endocrine-related Cancer·Stefano MangiolaNiall M Corcoran
Oct 1, 2008·British Journal of Cancer·N W Clarke
Sep 8, 2010·Nature Reviews. Urology·Oliver Sartor
Mar 20, 2008·Nature Clinical Practice. Urology·Jared M Whitson, Badrinath R Konety
Oct 30, 2007·Nature Clinical Practice. Oncology·Hashim Uddin AhmedMark Emberton
Feb 18, 2016·Journal of Biomedical Optics·Johannes SwartlingAnne-Sofie Lagerstedt
Jan 18, 2011·The Journal of Urology·Scott E EggenerAndrew J Stephenson
Oct 9, 2007·The Cancer Journal·Nicholas J van As, Chris C Parker
Jun 24, 2008·World Journal of Urology·Helen O'Donnell, Chris Parker
Jul 29, 2008·International Journal of Cancer. Journal International Du Cancer·Richard M MartinTom I L Nilsen

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

ProtecT
MIcrosimulation SCreening ANalysis ( MISCAN )
PIVOT
Stata
MISCAN

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.